Business
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its
About this update from Insulet Corporation
[{"type":"text","content":" ACTON, Mass.--(BUSINESS WIRE)--\nInsulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of Type 1 Diabetes (RADIANT). The results will be shared at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place March 19 – 22, 2025 in Amsterdam, the Netherlands, and online.\n\nThe study assessed changes in HbA1c as well as time in target glucose range (TIR) for people aged 4 to 70 years living with type 1 diabetes in France, the U.K., and Belgium using Omnipod 5, compared with those using multiple daily injections (MDI) with a continuous glucose monitor (CGM). RADIANT is the first randomized controlled trial to assess the direct transition from MDI to an automated insulin delivery (AID) system in adults and children who were not previously achieving clinical targets for HbA1c with MDI. It is also the first randomized clinical trial to assess the safety and efficacy of an AID system paired with an Abbott FreeStyle Libre® 2 family sensor.\n\nThe RADIANT results will be discussed at an Insulet-sponsored symposium, “Transform Your Clinical Care with Omnipod 5: Revolutionizing Diabetes Management,” being held on Wednesday, March 19 from 2:40 p.m. – 4:10 p.m. CET in Hall E.\n\nThe symposium will be presented by:\n\n\nDr. Emma Wilmot, PhD, FRCP, Associate Professor, University of Nottingham, School of Medicine, Nottingham, U.K. – Omnipod 5 Delivers Transformative Glycemic Outcomes – Sharing the Latest Breaking Results\n\n\nDr. Chantal Mathieu, MD, PhD, Professor of Medicine, Katholieke Universiteit Leuven, Belgium – How Omnipod 5 is Providing an Unparalleled User Experience\n\n\nDr. Brynn Marks, MD, MSHPEd, Director of Technology and Attending Physician, Children’s Hospital of Philadelphia, Assistant Professor, CE Perelman School of Medicine of the University of Pennsylvania, U.S. – Accelerating AID for All – Reaching the Broadest Populations Effectively\n\n\nDr. Trang Ly, MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer, will provide a Company update on future innovations at the sym...